The dynamics of the glioma market are anticipated to change in the coming years owing to the positive outcomes of the emerging pipeline candidates during the developmental stage by key players, such as Bayer, VBL Therapeutics, Candel Therapeutics, AstraZeneca, DNAtrix, DelMar Pharmaceuticals, Chimerix, KaryoPharma, VBI Vaccines, Kazia Therapeutics, and others
LAS VEGAS, May 1, 2023 /PRNewswire/ -- DelveInsight's Glioma Market Insights report includes a comprehensive understanding of current treatment practices, glioma emerging drugs, market share of individual therapies, and current and forecasted market size from 2019 to 2032, segmented into 7MM [the United States, the EU-4 (Italy, Spain, France, and Germany), the United Kingdom, and Japan].
Key Takeaways from the Glioma Market Report
- As per DelveInsight analysis, the glioma market size in the 7MM was approximately USD 1 billion in 2022.
- According to the assessment done by DelveInsight, the estimated total incident glioma cases in the 7MM were approximately 47K in 2022.
- Leading glioma companies such as Bayer, Chimerix, Aivita Biomedical, Denovo Biopharma, Northwest Therapeutics, VBL Therapeutics, Laminar Pharmaceuticals, MedImmune, DNAtrix, Immunomic Therapeutics, Imvax, MimiVax, CNS Pharmaceuticals, Epitopoietic Research Corporation (ERC), Istari Oncology, SonALAsense, Kintara Therapeutics, Bristol Myers Squibb, Medicenna Therapeutics, BioMimetix, Eisai and Merck Sharp & Dohme, Kazia Therapeutics, Oblato, Genenta Science, Enterome, Inovio Pharmaceuticals, Karyopharm Therapeutics, VBI Vaccines, TME Pharma, Day One Biopharmaceuticals, Servier, Orbus Therapeutics, TVAX Biomedical, AnHeart Therapeutics, Beigene, SpringWorks Therapeutics, Forma Therapeutics, Hoffmann-La Roche, Incyte Corporation, Eli Lilly, and others are developing novel glioma drugs that can be available in the glioma market in the coming years.
- The promising glioma therapies in the pipeline include Regorafenib, ONC201, AV-GBM-1, Enzastaurin (DB-102), DCVax-L, Ofranergene Obadenovec (VB-111), LAM561 (2-OHOA), MEDI4736 (durvalumab), Tasadenoturev (DNX-2401), ITI-1000 (pp65 DC Vaccine), IGV-001, SurVaxM, Berubicin, GLIOVAC (Sitoiganap), Lerapolturev + Pembrolizumab, SONALA-001 + Exablate 2.0 Device, VAL-083 (dianhydrogalactitol), Pomalidomide, MDNA55, BMX-001, Lenvatinib ± Pembrolizumab, Paxalisib (GDC-0084), OKN-007, Temferon, EO2401, INO-5401+ INO-9012+ LIBTAYO (cemiplimab), Selinexor (KPT-330), Olutasidenib (FT-2102), VBI-1901, NOX-A12 (Olaptesed Pegol), Tovorafenib (DAY101), Vorasidenib (AG-881), Eflornithine, TVI-Brain-1, AB-218, BGB-290, Mirdametinib, FT-2102 (Olutasidenib), Vinblastine + Bevacizumab, Cobimetinib, PEMAZYRE (Pemigatinib), VERZENIO (abemaciclib), and others.
- In December 2022, Chimerix announced the successful launch of the ONC201 Phase III ACTION study in patients with H3 K27M-mutant glioma.
- In June 2022, Day One Biopharmaceuticals announced positive initial data from its pivotal Phase II (FIREFLY-1) study with tovorafenib (DAY101) in relapsed pediatric low-grade glioma (pLGG).
Discover which therapies are expected to grab the major glioma market share @ Glioma Market Report
Glioma Overview
Glioma is the most common kind of glial cell tumor in the central nervous system (CNS). Gliomas are infiltrative tumors that affect the brain tissue surrounding them. Glioblastoma is the most hazardous type of brain tumor, whereas pilocytic astrocytomas are the least dangerous. Previously, diffuse gliomas were classified into subgroups and grades depending on histopathologies, such as diffuse astrocytomas, oligodendrogliomas, or mixed gliomas/oligoastrocytomas. The specific etiology of glioma, like other primary brain tumors, remains unknown. However, certain variables may increase the risk of getting a brain tumor. Glioma symptoms vary depending on tumor type, size, location, and growth rate. Some common glioma symptoms include headache, nausea or vomiting, memory loss, urine incontinence, speech problems, and others. A medical history and a physical examination are used for glioma diagnosis.
Glioma Epidemiology Segmentation
DelveInsight estimates that there were approximately 47K incident cases of glioma in the 7MM in 2022.
As per our analysis, the United States contributed to the largest incident population of glioma, acquiring ~40% of the 7MM in 2022.
The glioma market report proffers epidemiological analysis for the study period 2019–2032 in the 7MM segmented into:
- Total glioma incident cases
- Glioma grade-specific cases
- Glioma age-specific cases
- Glioma type-specific cases
Download the report to understand which factors are driving glioma epidemiology trends @ Glioma Epidemiological Insights
Glioma Treatment Market
Glioma treatment is based on the type of glioma, its size and location, and the patient's unique characteristics. Chemotherapy and radiation therapy will be administered after surgery, particularly in individuals when the tumor cannot be removed entirely because it has invaded critical parts of the brain or is inaccessible. The typical glioma treatment protocol comprises surgery, chemotherapy, and radiation. Chemotherapy may include carmustine (BCNU), lomustine (CCNU), or gleostine (generic), cisplatin, carboplatin, etoposide, and irinotecan in case of low-grade glioma whereas temozolomide (TEMODAR) is the standard chemotherapy used in case of high-grade glioma majorly, Gliadel wafer implants (biodegradable discs injected with BCNU) are usually given as adjunctive treatment after surgery, although usage of Gliadel wafers remains a point of controversy due to its questionable survival benefits. Avastin (Genentech) and Temodar/Temodal (Merck), among others, are approved medications for HGG. However, due to patent expiration, the generic version of Temodar and biosimilars of Avastin are available on the glioma market. As generics and biosimilars are more cost-effective for patients than new medicines, intense competition exists among them. Furthermore, due to a lack of knowledge concerning bevacizumab's overall survival benefit, it is not recommended in unselected patients with newly diagnosed GBM. Currently, only one medication for LGG is approved, Tafinlar (dabrafenib) plus Mekinist (trametinib).
Moreover, the current therapeutic market lacks a viable method for curing glioblastoma; therefore, the survival rate of people diagnosed with glioma remains poor. Glioma is incurable, and treatment choices are limited. Furthermore, the tumor has a high recurrence rate and a poor patient prognosis. In addition, there is currently no approved therapy for the unmethylated MGMT patient pool.
To know more about glioma treatment guidelines, visit @ Glioma Management
Glioma Therapies and Key Companies
- Regorafenib: Bayer
- ONC201: Chimerix
- AV-GBM-1: Aivita Biomedical
- Enzastaurin (DB-102): Denovo Biopharma
- DCVax-L: Northwest Therapeutics
- Ofranergene Obadenovec (VB-111): VBL Therapeutics
- LAM561 (2-OHOA): Laminar Pharmaceuticals
- MEDI4736 (durvalumab): MedImmune
- Tasadenoturev (DNX-2401): DNAtrix
- ITI-1000 (pp65 DC Vaccine): Immunomic Therapeutics
- IGV-001: Imvax
- SurVaxM: MimiVax
- Berubicin: CNS Pharmaceuticals
- GLIOVAC (Sitoiganap): Epitopoietic Research Corporation (ERC)
- Lerapolturev + Pembrolizumab: Istari Oncology
- SONALA-001 + Exablate 2.0 Device: SonALAsense
- VAL-083 (dianhydrogalactitol): Kintara Therapeutics
- Pomalidomide: Bristol Myers Squibb
- MDNA55: Medicenna Therapeutics
- BMX-001: BioMimetix
- Lenvatinib ± Pembrolizumab: Eisai and Merck Sharp & Dohme
- Paxalisib (GDC-0084): Kazia Therapeutics
- OKN-007: Oblato
- Temferon: Genenta Science
- EO2401: Enterome
- INO-5401+ INO-9012+ LIBTAYO (cemiplimab): Inovio Pharmaceuticals
- Selinexor (KPT-330): Karyopharm Therapeutics
- VBI-1901: VBI Vaccines
- NOX-A12 (Olaptesed Pegol): TME Pharma
- Tovorafenib (DAY101): Day One Biopharmaceuticals
- Vorasidenib (AG-881): Servier
- Eflornithine: Orbus Therapeutics
- TVI-Brain-1: TVAX Biomedical
- AB-218: AnHeart Therapeutics
- BGB-290: Beigene
- Mirdametinib: SpringWorks Therapeutics
- FT-2102 (Olutasidenib): Forma Therapeutics
- Vinblastine + Bevacizumab: Hoffmann-La Roche
- Cobimetinib: Hoffmann-La Roche
- PEMAZYRE (Pemigatinib): Incyte Corporation
- VERZENIO (abemaciclib): Eli Lilly
Learn more about the FDA-approved drugs for glioma @ Drugs for Glioma Treatment
Glioma market growth can be ascribed to various factors, including an aging population, evolving research, better diagnostic tests, developing surgical procedures, improved radiotherapy techniques, and novel systemic medicines.
Commercially, there is a greater emphasis on high-grade glioma than low-grade glioma because patients with low-grade glioma often live longer than those with high-grade glioma. As a result, just a few therapies are in late-stage studies, while the majority are in early-stage trials. In the case of GBM, on the other hand, the pipeline is robust, with numerous potential therapies in late and mid-stage research that have yet to be marketed. The pipeline includes drugs with varied modes of action and administration routes. It is interesting to note that the emerging market of glioma includes budding gene therapy, i.e., ofranergene obadenovec (VB-111) by VBL Therapeutics, followed by four vaccine/immunotherapy candidates such as VBI-1901, AV-GBM-1 and ITI-1000 (pp65 DC Vaccine), tasadenoturev (DNX-2401) by VBI Vaccines, Aivita Biomedical, Immunomic Therapeutics, and DNAtrix, respectively, and these therapies are going to alter the glioma market dynamics in the upcoming years.
The current glioma market has been categorized based on the dominant treatment pattern across the 7MM, which shows slight variances in the overall prescription pattern. The forecast model considers surgery, chemotherapy/radiation therapy, bevacizumab + radiotherapy/chemotherapy, and OPTUNE with temozolomide. The anticipated launch of new therapies and improved integration of early patient screening, medication in secondary care and other clinical settings, research on optimum implementation methods, and increased awareness may eventually facilitate the development of successful treatment alternatives.
However, there are a few challenges to the timely identification and treatment of these patients, such as a lack of a reliable biomarker that can aid in diagnosis and patient classification and identifying recurrence and signaling medication response. Furthermore, the failure rate of high-phased drug trials is significant, making it impossible to predict trial success, exacerbating the need for medicines that could assist ease the patient segment with this severe kind of cancer.
Report Metrics |
Details |
Study Period |
2019–2032 |
Coverage |
7MM [the United States, the EU-4 (Italy, Spain, France, and Germany), the United Kingdom, and Japan] |
Base Year |
2019 |
Glioma Market CAGR |
Approx.13% |
Glioma Market Size in 2022 |
USD 1,000 million |
Key Glioma Companies |
Bayer, Chimerix, Aivita Biomedical, Denovo Biopharma, Northwest Therapeutics, VBL Therapeutics, Laminar Pharmaceuticals, MedImmune, DNAtrix, Immunomic Therapeutics, Imvax, MimiVax, CNS Pharmaceuticals, Epitopoietic Research Corporation (ERC), Istari Oncology, SonALAsense, Kintara Therapeutics, Bristol Myers Squibb, Medicenna Therapeutics, BioMimetix, Eisai and Merck Sharp & Dohme, Kazia Therapeutics, Oblato, Genenta Science, Enterome, Inovio Pharmaceuticals, Karyopharm Therapeutics, VBI Vaccines, TME Pharma, Day One Biopharmaceuticals, Servier, Orbus Therapeutics, TVAX Biomedical, AnHeart Therapeutics, Beigene, SpringWorks Therapeutics, Forma Therapeutics, Hoffmann-La Roche, Incyte Corporation, Eli Lilly, and others |
Key Pipeline Glioma Therapies |
Regorafenib, ONC201, AV-GBM-1, Enzastaurin (DB-102), DCVax-L, Ofranergene Obadenovec (VB-111), LAM561 (2-OHOA), MEDI4736 (durvalumab), Tasadenoturev (DNX-2401), ITI-1000 (pp65 DC Vaccine), IGV-001, SurVaxM, Berubicin, GLIOVAC (Sitoiganap), Lerapolturev + Pembrolizumab, SONALA-001 + Exablate 2.0 Device, VAL-083 (dianhydrogalactitol), Pomalidomide, MDNA55, BMX-001, Lenvatinib ± Pembrolizumab, Paxalisib (GDC-0084), OKN-007, Temferon, EO2401, INO-5401+ INO-9012+ LIBTAYO (cemiplimab), Selinexor (KPT-330), Olutasidenib (FT-2102), VBI-1901, NOX-A12 (Olaptesed Pegol), Tovorafenib (DAY101), Vorasidenib (AG-881), Eflornithine, TVI-Brain-1, AB-218, BGB-290, Mirdametinib, FT-2102 (Olutasidenib), Vinblastine + Bevacizumab, Cobimetinib, PEMAZYRE (Pemigatinib), VERZENIO (abemaciclib), and others |
Scope of the Glioma Market Report
- Therapeutic Assessment: Glioma current marketed and emerging therapies
- Glioma Market Dynamics: Conjoint Analysis of Emerging Glioma Drugs
- Competitive Intelligence Analysis: SWOT analysis and Market entry strategies
- Unmet Needs, KOL's Views, Analyst's Views, Glioma Market Access and Reimbursement
Discover more about glioma drugs in development @ Glioma Clinical Trials
Table to Contents
1 |
Key Insights |
2 |
Report Introduction |
3 |
Executive Summary |
4 |
Key Events |
5 |
Epidemiology and Market Forecast Methodology |
6 |
Glioma Market Overview at a Glance |
6.1 |
Market Share (%) Distribution of Glioma by Therapies in 2022 |
6.2 |
Market Share (%) Distribution of Glioma by Therapies in 2032 |
7 |
Disease Background and Overview: Gliomas |
7.1 |
Introduction |
7.2 |
Classification of gliomas |
7.2.1 |
Low-grade Gliomas |
7.2.2 |
High-grade Gliomas |
7.3 |
Signs and symptoms |
7.4 |
Causes |
7.5 |
Diagnosis |
7.5.1 |
Neurological exams |
7.5.2 |
Angiograms |
7.5.3 |
Computerized tomography (CT) |
7.5.4 |
Magnetic resonance imaging (MRI) |
7.5.5 |
Perfusion MRI |
7.5.6 |
MR spectroscopy |
7.5.7 |
Histological diagnosis |
7.5.8 |
Surgical biopsy |
8 |
Treatment and management |
8.1 |
Treatment of LGGs |
8.2 |
Treatment of HGGs |
8.3 |
Symptom management |
8.4 |
Treatment guidelines and recommendations |
8.4.1 |
American Society of Clinical Oncology (ASCO) Endorsed American Society for Radiation Oncology (ASTRO) Guideline on Radiation Therapy for Glioblastoma (2017) |
8.4.2 |
American Society of Therapeutic Radiology and Oncology (ASTRO) Clinical Practice Guideline for LGGs (2021) |
8.4.3 |
National Comprehensive Cancer Network [NCCN] Guidelines for the Management of Gliomas (2022) |
8.4.4 |
National Institute for Health and Care Excellence Guidelines for the Management of Newly Diagnosed Glioblastoma (2021) |
8.4.5 |
Japanese Society of Neurological Surgery Guidelines for the Treatment of Adult Glioblastoma (2019) |
8.4.6 |
Society for Neuro-Oncology (SNO) and European Society of Neuro-Oncology (EANO) Consensus Review on Current Management and Future Directions for Glioblastoma in Adults (2020) |
8.4.7 |
Clinical Recommendation for Glioblastoma (Associazione Italiana di Oncologia Medica [AIOM], 2021) |
8.4.8 |
Medical Oncology Spanish Society (SEOM) Clinical Guidelines for Diagnosis and Treatment of Glioblastoma |
8.4.9 |
European Association of Neuro-Oncology (EANO) Guidelines for the Diagnosis and Management of Adult Patients with Diffuse Gliomas (2021) |
8.4.10 |
SEOM Guideline Recommendations for LGGs (2017) |
9 |
Epidemiology and Patient Population of Glioma in the 7MM |
9.1 |
Key Findings |
9.2 |
Assumptions and Rationale |
9.3 |
Total Incident Cases of Glioma in the 7MM |
9.4 |
The United States |
9.4.1 |
Total Incident Cases of Glioma in the United States |
9.4.2 |
Grade-specific Cases of Glioma in the United States |
9.4.3 |
Age-specific Cases of Glioma in the United States |
9.4.4 |
Type-specific Cases of Glioma in the United States |
9.5 |
EU4 and the UK |
9.5.1 |
Total Incident Cases of Glioma in EU4 and the UK |
9.5.2 |
Grade-specific Cases of Glioma in EU4 and the UK |
9.5.3 |
Age-specific Cases of Glioma in EU4 and the UK |
9.5.4 |
Type-specific Cases of Glioma in EU4 and the UK |
9.6 |
Japan |
9.6.1 |
Total Incident Cases of Glioma in Japan |
9.6.2 |
Grade-specific Cases of Glioma in Japan |
9.6.3 |
Age-specific Cases of Glioma in Japan |
9.6.4 |
Type-specific cases of Glioma in Japan |
10 |
Patient Journey |
11 |
Key Endpoints in Glioma |
12 |
Marketed Products |
12.1 |
Key Competitors |
12.2 |
OPTUNE: Novocure Limited |
12.2.1 |
Product description |
12.2.2 |
Regulatory milestones |
12.2.3 |
Other developmental activities |
12.2.4 |
Current pipeline activity |
12.2.5 |
Safety and efficacy |
12.2.6 |
Product profile |
12.3 |
AVASTIN (bevacizumab): Genentech |
12.3.1 |
Product description |
12.3.2 |
Regulatory milestones |
12.3.3 |
Other developmental activities |
12.3.4 |
Safety and efficacy |
12.3.5 |
Product profile |
12.4 |
TEMODAR (temozolomide): Merck |
12.4.1 |
Product description |
12.4.2 |
Regulatory milestones |
12.4.3 |
Other development activities |
12.4.4 |
Current pipeline activity |
12.4.5 |
Safety and efficacy |
12.4.6 |
Product profile |
12.5 |
DELYTACT: Daiichi Sankyo |
12.5.1 |
Product description |
12.5.2 |
Regulatory milestones |
12.5.3 |
Other developmental activities |
12.5.4 |
Safety and efficacy |
12.5.5 |
Product profile |
12.6 |
TAFINLAR (dabrafenib) + MEKINIST (trametinib): Novartis |
12.6.1 |
Product description |
12.6.2 |
Regulatory milestones |
12.6.3 |
Other Developmental Activities |
12.6.4 |
Clinical development |
12.6.5 |
Safety and efficacy |
12.6.6 |
Product profile |
13 |
Emerging Drugs |
13.1 |
Key Competitors |
13.2 |
Regorafenib: Bayer |
13.2.1 |
Product description |
13.2.2 |
Other developmental activities |
13.2.3 |
Clinical development |
13.2.4 |
Safety and efficacy |
13.3 |
ONC201: Chimerix |
13.3.1 |
Product description |
13.3.2 |
Other developmental activities |
13.3.3 |
Clinical development |
13.3.4 |
Safety and efficacy |
13.4 |
AV-GBM-1: Aivita Biomedical |
13.4.1 |
Product description |
13.4.2 |
Clinical development |
13.4.3 |
Safety and efficacy |
13.5 |
Enzastaurin (DB-102): Denovo Biopharma |
13.5.1 |
Product description |
13.5.2 |
Other developmental activities |
13.5.3 |
Clinical development |
13.5.4 |
Safety and efficacy |
13.6 |
DCVax-L: Northwest Therapeutics |
13.6.1 |
Product description |
13.6.2 |
Other developmental activity |
13.6.3 |
Clinical development |
13.6.4 |
Safety and efficacy |
13.7 |
Ofranergene Obadenovec (VB-111): VBL Therapeutics |
13.7.1 |
Product Description |
13.7.2 |
Other Developmental Activities |
13.7.3 |
Clinical development |
13.7.4 |
Safety and efficacy |
13.8 |
LAM561 (2-OHOA): Laminar Pharmaceuticals |
13.8.1 |
Product description |
13.8.2 |
Other developmental activities |
13.8.3 |
Clinical development |
13.8.4 |
Safety and efficacy |
13.9 |
MEDI4736 (durvalumab): MedImmune |
13.9.1 |
Product description |
13.9.2 |
Clinical Development |
13.9.3 |
Safety and efficacy |
13.1 |
Tasadenoturev (DNX-2401): DNAtrix |
13.10.1 |
Product description |
13.10.2 |
Other developmental activities |
13.10.3 |
Clinical development |
13.10.4 |
Safety and efficacy |
13.11 |
ITI-1000 (pp65 DC Vaccine): Immunomic Therapeutics |
13.11.1 |
Product description |
13.11.2 |
Other developmental activities |
13.11.3 |
Clinical development |
13.11.4 |
Safety and efficacy |
13.12 |
IGV-001: Imvax |
13.12.1 |
Product description |
13.12.2 |
Other developmental activities |
13.12.3 |
Clinical development |
13.12.4 |
Safety and efficacy |
13.13 |
SurVaxM: MimiVax |
13.13.1 |
Product description |
13.13.2 |
Other developmental activities |
13.13.3 |
Clinical development |
13.13.4 |
Safety and efficacy |
13.14 |
Berubicin: CNS Pharmaceuticals |
13.14.1 |
Product description |
13.14.2 |
Other developmental activities |
13.14.3 |
Clinical development |
13.14.4 |
Safety and efficacy |
13.15 |
GLIOVAC (Sitoiganap): Epitopoietic Research Corporation (ERC) |
13.15.1 |
Product description |
13.15.2 |
Other developmental activities |
13.15.3 |
Clinical development |
13.15.4 |
Safety and efficacy |
13.16 |
Lerapolturev + Pembrolizumab: Istari Oncology |
13.16.1 |
Product description |
13.16.2 |
Other developmental activities |
13.16.3 |
Clinical development |
13.16.4 |
Safety and efficacy |
13.17 |
SONALA-001 + Exablate 2.0 Device: SonALAsense |
13.17.1 |
Product description |
13.17.2 |
Clinical development |
13.17.3 |
Safety and efficacy |
13.18 |
VAL-083 (dianhydrogalactitol): Kintara Therapeutics |
13.18.1 |
Product description |
13.18.2 |
Other developmental activities |
13.18.3 |
Clinical development |
13.18.4 |
Safety and efficacy |
13.19 |
Pomalidomide: Bristol Myers Squibb |
13.19.1 |
Product description |
13.19.2 |
Other developmental activities |
13.19.3 |
Clinical development |
13.19.4 |
Safety and efficacy |
13.2 |
MDNA55: Medicenna Therapeutics |
13.20.1 |
Product description |
13.20.2 |
Other developmental activities |
13.20.3 |
Clinical development |
13.20.4 |
Safety and efficacy |
13.21 |
BMX-001: BioMimetix |
13.21.1 |
Product description |
13.21.2 |
Other developmental activity |
13.21.3 |
Clinical development |
13.21.4 |
Safety and efficacy |
13.22 |
Lenvatinib ± Pembrolizumab: Eisai and Merck Sharp & Dohme |
13.22.1 |
Product description |
13.22.2 |
Clinical development |
13.22.3 |
Safety and efficacy |
13.23 |
Paxalisib (GDC-0084): Kazia Therapeutics |
13.23.1 |
Product description |
13.23.2 |
Other developmental activities |
13.23.3 |
Clinical development |
13.23.4 |
Safety and efficacy |
13.24 |
OKN-007: Oblato |
13.24.1 |
Product description |
13.24.2 |
Other developmental Activity |
13.24.3 |
Clinical development |
13.24.4 |
Safety and efficacy |
13.25 |
Temferon: Genenta Science |
13.25.1 |
Product description |
13.25.2 |
Clinical development |
13.25.3 |
Safety and efficacy |
13.26 |
EO2401: Enterome |
13.26.1 |
Product description |
13.26.2 |
Clinical development |
13.26.3 |
Safety and efficacy |
13.27 |
INO-5401+ INO-9012+ LIBTAYO (cemiplimab): Inovio Pharmaceuticals |
13.27.1 |
Product description |
13.27.2 |
Clinical development |
13.27.3 |
Safety and efficacy |
13.28 |
Selinexor (KPT-330): Karyopharm Therapeutics |
13.28.1 |
Product description |
13.28.2 |
Clinical development |
13.28.3 |
Safety and efficacy |
13.29 |
Olutasidenib (FT-2102): Forma Therapeutics |
13.29.1 |
Product description |
13.29.2 |
Other developmental activities |
13.29.3 |
Clinical development |
13.29.4 |
Safety and efficacy |
13.3 |
VBI-1901: VBI Vaccines |
13.30.1 |
Product description |
13.30.2 |
Other developmental activities |
13.30.3 |
Clinical development |
13.30.4 |
Safety and efficacy |
13.31 |
NOX-A12 (Olaptesed Pegol): TME Pharma |
13.31.1 |
Product description |
13.31.2 |
Other developmental activities |
13.31.3 |
Clinical development |
13.31.4 |
Safety and efficacy |
13.32 |
Tovorafenib (DAY101): Day One Biopharmaceuticals |
13.32.1 |
Product description |
13.32.2 |
Other developmental activities |
13.32.3 |
Clinical development |
13.32.4 |
Safety and efficacy |
13.33 |
Vorasidenib (AG-881): Servier |
13.33.1 |
Product description |
13.33.2 |
Other developmental activities |
13.33.3 |
Clinical development |
13.33.4 |
Safety and efficacy |
13.34 |
Eflornithine: Orbus Therapeutics |
13.34.1 |
Product description |
13.34.2 |
Other developmental activities |
13.34.3 |
Clinical development |
13.34.4 |
Safety and efficacy |
13.35 |
TVI-Brain-1: TVAX Biomedical |
13.35.1 |
Product description |
13.35.2 |
Other developmental activities |
13.35.3 |
Clinical development |
13.36 |
AB-218: AnHeart Therapeutics |
13.36.1 |
Product description |
13.36.2 |
Other developmental activities |
13.36.3 |
Clinical development |
13.36.4 |
Safety and efficacy |
13.37 |
BGB-290: Beigene |
13.37.1 |
Product description |
13.37.2 |
Clinical development |
13.37.3 |
Safety and efficacy |
13.38 |
Mirdametinib: SpringWorks Therapeutics |
13.38.1 |
Product description |
13.38.2 |
Other developmental activities |
13.38.3 |
Clinical development |
13.38.4 |
Safety and efficacy |
13.39 |
Vinblastine + Bevacizumab: Hoffmann-La Roche |
13.39.1 |
Product description |
13.39.2 |
Clinical development |
13.39.3 |
Safety and efficacy |
13.4 |
Cobimetinib: Hoffmann-La Roche |
13.40.1 |
Product description |
13.40.2 |
Clinical development |
13.40.3 |
Safety and efficacy |
13.41 |
PEMAZYRE (Pemigatinib): Incyte Corporation |
13.41.1 |
Product description |
13.41.2 |
Clinical development |
13.42 |
VERZENIO (abemaciclib): Eli Lilly |
13.42.1 |
Product description |
13.42.2 |
Clinical development |
13.42.3 |
Safety and efficacy |
14 |
Glioma: Seven Major Market Analysis |
14.1 |
Key Findings |
14.2 |
Market Outlook |
14.3 |
Key Market Forecast Assumptions |
14.4 |
Conjoint Analysis |
14.5 |
Total Market Size of Glioma in the 7MM |
14.6 |
United States Market Size |
14.6.1 |
Total Market size of Glioma in the United States |
14.6.2 |
Market Size of Glioma by Current and Emerging Therapies in the United States |
14.7 |
EU4 and UK Market Size |
14.7.1 |
Total Market size of Glioma in EU4 and the UK |
14.7.2 |
Market Size of Glioma by Current and Emerging Therapies in EU4 and the UK |
14.8 |
Japan Market Size |
14.8.1 |
Total Market size of Glioma in Japan |
14.8.2 |
Market Size of Glioma by Current and Emerging Therapies in Japan |
15 |
Unmet Needs |
16 |
SWOT Analysis |
17 |
KOL Views |
18 |
Market Access and Reimbursement for Glioma |
18.1 |
United States |
18.2 |
Europe |
18.3 |
Japan |
19 |
Appendix |
19.1 |
Bibliography |
19.2 |
Report Methodology |
20 |
DelveInsight Capabilities |
21 |
Disclaimer |
22 |
About DelveInsight |
Related Reports
Glioma Epidemiology Forecast – 2032 report delivers an in-depth understanding of the disease, historical and forecasted glioma epidemiology in the 7MM, i.e., the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan.
Glioma Pipeline Insight – 2023 report provides comprehensive insights about the pipeline landscape, pipeline drug profiles, including clinical and non-clinical stage products, and the key glioma companies, including PTC Therapeutics, Ono Pharmaceuticals, Philogen, SpringWorks Therapeutics, Xennials Therapeutics, AnHeart Therapeutics, Istari Oncology, among others.
High-Grade Glioma Pipeline Insight – 2023 report provides comprehensive insights about the pipeline landscape, pipeline drug profiles, including clinical and non-clinical stage products, and the key high-grade glioma companies, including PTC Therapeutics, Aadi, Lee's Pharmaceutical, among others.
Malignant Glioma Pipeline Insight – 2023 report provides comprehensive insights about the pipeline landscape, pipeline drug profiles, including clinical and non-clinical stage products, and the key malignant glioma companies, including Bexion Pharmaceuticals, Inc., Lee's Pharmaceutical Limited, Merck & Co, Oblato, Inc., OncoSynergy, Inc, among others.
Recurrent Malignant Glioma Pipeline
Recurrent Malignant Glioma Pipeline Insight – 2023 report provides comprehensive insights about the pipeline landscape, pipeline drug profiles, including clinical and non-clinical stage products, and the key recurrent malignant glioma companies, including Bexion Pharmaceuticals, Inc., Merck, Oblato, OncoSynergy, Inc, among others.
Glioblastoma Pipeline Insight – 2023 report provides comprehensive insights about the pipeline landscape, pipeline drug profiles, including clinical and non-clinical stage products, and the key glioblastoma companies, including AstraZeneca, BioNTech, Merck, Pfizer, Roche, among others.
Other Trending Reports
Tay-sachs Disease Or Gm2 Gangliosidosis Market | Onycholysis Market | Diagnostic Imaging Equipment Market | Chemotherapy-induced Peripheral Neuropathy Market | Global Electrophysiology Devices Market | Anaphylaxis Market | Atherectomy Devices Market | Helicobacter Pylori Infections Market | Ophthalmic Imaging Equipment Market | Androgenetic Alopecia Market | Allergic Rhinitis Market | Chronic Inflammatory Demyelinating Polyneuropathy Market | Chronic Inflammatory Demyelinating Polyneuropathy Market | Colorectal Cancer Crc Market | Opioid Induced Constipation Market | Vertigo Market | Bone Anchored Hearing Systems Market | Wound Closure Devices Market | Hip Replacement Devices Market | Hemodynamic Monitoring Systems Market | Egfr Non-small Cell Lung Cancer Market | Helicobacter Pylori Infection Market | Hyperkalemia Market | Polycythemia Market Neurostimulation Devices Market | Carpal Tunnel Syndrome Market | Ventilator Market | Cerebral Aneurysm Market | Alpha Antitrypsin Market | Binge Eating Disorder Market | Bunion Market | Concussions Market Size | Exocrine Pancreatic Insufficiency Market | Healthcare Due Diligence Services | Minimal Residual Disease Market | Hypertrophic Scar Market | Lung Fibrosis Market | Anterior Uveitis Market | 22q11.2 deletion syndrome Market | X-Linked Retinitis Pigmentosa (XLRP) Market | Acute Radiation Syndrome Market | Alpha-1 Protease Inhibitor Deficiency Market | Androgenetic Alopecia Market | Hyperlipidemia Market | Cardiotoxicity Market | Hypertrophic Cardiomyopathy Market | Fatty Acid Oxidation Disorders (FAODs) Market | Androgen Insensitivity Syndrome Market | Emphysema Market | Canaloplasty Market | Dravet Syndrome Market | Celiac Disease Market | Chlamydia Infections Market | Syphilis Market | Renal Tubular Acidosis Market | Palmoplantar Pustulosis (PPP) Market | Aplastic Anemia Market | Bacterial Pneumonia Market | B cell Chronic Lymphocytic Leukemia Market | B cell Lymphomas Market | Behcets Disease Market Neoantigen-based Personalized Cancer therapeutic Vaccines Competitive Landscape and Market Forecast—by 2035 | Glioblastoma Market
Related Healthcare Services
Healthcare Competitive Intelligence Services
Healthcare Asset Prioritization Services
About DelveInsight
DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance. Get hassle-free access to all the healthcare and pharma market research reports through our subscription-based platform PharmDelve.
Connect with us on LinkedIn|Facebook|Twitter
Contact Us
Shruti Thakur
[email protected]
+1(919)321-6187
www.delveinsight.com
Logo: https://mma.prnewswire.com/media/1082265/DelveInsight_Logo.jpg
SOURCE DelveInsight Business Research, LLP
![](https://rt.prnewswire.com/rt.gif?NewsItemId=IO86060&Transmission_Id=202305011100PR_NEWS_USPR_____IO86060&DateId=20230501)
Share this article